LAVAL, QC, Sept. 16 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today
announced that Mark D'Souza, Senior Vice-President and Chief Financial Officer
of the Company, will present at the CIBC World Markets 7th Annual Eastern
Institutional Investor Conference at the Le Centre Sheraton Hotel in Montreal
on Tuesday, September 23, 2008 at 10:35 a.m. ET.
Interested parties may access the live audio webcast for this
presentation by visiting the "Events" section of the homepage of the Company's
website at www.labopharm.com. Please connect at least 15 minutes prior to the
presentation to ensure adequate time for any software download that may be
required to join the webcast. An audio archive of the presentation will be
available for 30 days.
About Labopharm Inc.
Labopharm is an emerging leader in optimizing the performance of existing
small molecule drugs using its proprietary controlled-release technologies.
The Company's lead product, a unique once-daily formulation of tramadol, is
being commercially launched in key markets globally. The Company also has a
robust pipeline of follow-on products in both pre-clinical and clinical
development. Labopharm's vision is to become an integrated, international,
specialty pharmaceutical company with the capability to internally develop and
commercialize its own products. For more information, please visit
This press release contains forward-looking statements, which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual events could differ
materially from those projected herein and depend on a number of factors,
including the uncertainties related to the regulatory process in various
countries for the approval of the Company's products and the successful
commercialization of the products throughout the world if they are approved.
Investors should consult the Company's ongoing quarterly filings and annual
reports for additional information on risks and uncertainties relating to
these forward-looking statements. The reader is cautioned not to rely on these
forward-looking statements. The Company disclaims any obligation to update
these forward-looking statements.
For further information:
For further information: At Labopharm: Mark D'Souza, Senior
Vice-President and Chief Financial Officer, Tel: (450) 686-0207; At The
Equicom Group: Jason Hogan, Media and Investor Relations, Tel: (416) 815-0700,
firstname.lastname@example.org; French: Joe Racanelli, Tel: (514) 844-7997,